The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the united states

Annals of Internal Medicine

Volumn 153, Issue 12, 2010, Pages 778-789

  Long, Elisa F ^a   Brandeau, Margaret L ^b   Owens, Douglas K ^c  

^a YALE SCHOOL OF MANAGEMENT   (United States)

^b Stanford University   (United States)

^c STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADOLESCENT; ADULT; ARTICLE; BISEXUALITY; CD4 LYMPHOCYTE COUNT; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DISEASE TRANSMISSION; EPIDEMIC; FEMALE; HIGH RISK BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PATIENT COUNSELING; PREVALENCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SCREENING TEST; SEXUAL BEHAVIOR; UNITED STATES;

EID: 78751631897     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-153-12-201012210-00004     Document Type: Article

References (104)

1. Centers for Disease Control and Prevention (CDC). Estimates of New HIV Infections in the United States; 2008. Accessed at www.cdc.gov/hiv/topics/ surveillance/resources/factsheets/incidence.htm on 1 August 2010.
2. Hall HI, Song R, Rhodes P, Prejean J, An Q, Lee LM, et al; HIV Incidence Surveillance Group. Estimation of HIV incidence in the United States. JAMA. 2008;300:520-9. [PMID: 18677024]
3. Branson BM, Handsfield HH, Lampe MA, Janssen RS, Taylor AW, Lyss SB, et al; Centers for Disease Control and Prevention (CDC). Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55:1-17. [PMID: 16988643]
4. The NIMH Multisite HIV Prevention Trial: reducing HIV sexual risk behavior. The National Institute of Mental Health (NIMH) Multisite HIV Prevention Trial Group. Science. 1998;280:1889-94. [PMID: 9632382]
5. Kamb ML, Fishbein M, Douglas JM Jr, Rhodes F, Rogers J, Bolan G, et al. Efficacy of risk-reduction counseling to prevent human immunodeficiency virus and sexually transmitted diseases: a randomized controlled trial. Project RESPECT Study Group. JAMA. 1998;280:1161-7. [PMID: 9777816]
6. Koblin B, Chesney M, Coates T; EXPLORE Study Team. Effects of a behavioural intervention to reduce acquisition of HIV infection among men who have sex with men: the EXPLORE randomized controlled study. Lancet. 2004;364:41-50. [PMID: 15234855]
7. Marks G, Crepaz N, Senterfitt JW, Janssen RS. Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs. J Acquir Immune Defic Syndr. 2005;39:446-53. [PMID: 16010168] (Pubitemid 41003791)
8. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000;342:921-9. [PMID: 10738050]
9. Vernazza P, Hirschel B, Bernasconi E, Flepp M. Les personnes seropositives ne souff rant d'aucune autre MST et suivant un traitment antiretroviral effi cie ne transmettent pas le VIH par voie sexuelle. Bull Med Suisses. 2008;89:165-69.
10. Castilla J, Del Romero J, Hernando V, Marincovich B, García S, Rodríguez C. Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J Acquir Immune Defic Syndr. 2005;40:96-101. [PMID: 16123689] (Pubitemid 41233212)
11. Porco TC, Martin JN, Page-Shafer KA, Cheng A, Charlebois E, Grant RM, et al. Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. AIDS. 2004;18:81-8. [PMID: 15090833] (Pubitemid 38402321)
12. Vernazza PL, Troiani L, Flepp MJ, Cone RW, Schock J, Roth F, et al. Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV. The Swiss HIV Cohort Study. AIDS. 2000;14:117-21. [PMID: 10708281]
13. Zhang H, Dornadula G, Beumont M, Livornese L Jr, Van Uitert B, Henning K, et al. Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. N Engl J Med. 1998;339:1803-9. [PMID: 9854115] (Pubitemid 29005784)
14. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, et al; 903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292:191-201. [PMID: 15249568]
15. Centers for Disease Control and Prevention (CDC). HIV and AIDS in the United States; 2010. Accessed at www.cdc.gov/hiv/resources/factsheets/us.htm on 1 August 2010.
16. Bartlett JG, Branson BM, Fenton K, Hauschild BC, Miller V, Mayer KH. Opt-out testing for human immunodeficiency virus in the United States: progress and challenges. JAMA. 2008;300:945-51. [PMID: 18728268]
17. Qaseem A, Snow V, Shekelle P, Hopkins R Jr, Owens DK; Clinical Efficacy Assessment Subcommittee, American College of Physicians. Screening for HIV in health care settings: a guidance statement from the American College of Physicians and HIV Medicine Association. Ann Intern Med. 2009;150:125-31. [PMID: 19047022]
18. Brandeau ML, Owens DK, Sox CH, Wachter RM. Screening women of childbearing age for human immunodeficiency virus. A cost-benefit analysis. Arch Intern Med. 1992;152:2229-37. [PMID: 1444682]
19. Brandeau ML, Owens DK, Sox CH, Wachter RM. Screening women of childbearing age for human immunodeficiency virus. A model-based policy analysis. Manage Sci. 1993;39:72-92.
20. Owens DK, Nease RF Jr, Harris RA. Cost-effectiveness of HIV screening in acute care settings. Arch Intern Med. 1996;156:394-404. [PMID: 8607724]
21. Sanders GD, Bayoumi AM, Sundaram V, Bilir SP, Neukermans CP, Rydzak CE, et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med. 2005;352:570-85. [PMID: 15703422] (Pubitemid 40204670)
22. Paltiel AD, Weinstein MC, Kimmel AD, Seage GR 3rd, Losina E, Zhang H, et al. Expanded screening for HIV in the United States - an analysis of cost-effectiveness. N Engl J Med. 2005;352:586-95. [PMID: 15703423] (Pubitemid 40204671)
23. Walensky RP, Freedberg KA, Weinstein MC, Paltiel AD. Cost-effectiveness of HIV testing and treatment in the United States. Clin Infect Dis. 2007;45Suppl 4:S248-54. [PMID: 18190295]
24. Paltiel AD, Walensky RP, Schackman BR, Seage GR 3rd, Mercincavage LM, Weinstein MC, et al. Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Ann Intern Med. 2006;145:797-806. [PMID: 17146064]
25. Owens DK, Sundaram V, Lazzeroni LC, Douglass LR, Sanders GD, Taylor K, et al. Prevalence of HIV infection among inpatients and outpatients in Department of Veterans Affairs health care systems: implications for screening programs for HIV. Am J Public Health. 2007;97:2173-8. [PMID: 17971545]
26. Sanders GD, Bayoumi AM, Holodniy M, Owens DK. Cost-effectiveness of HIV screening in patients older than 55 years of age. Ann Intern Med. 2008;148:889-903. [PMID: 18559840] (Pubitemid 351860821)
27. Sanders GD, Anaya HD, Asch S, Hoang T, Golden JF, Bayoumi AM, et al. Cost-effectiveness of strategies to improve HIV testing and receipt of results: economic analysis of a randomized controlled trial. J Gen Intern Med. 2010;25:556-63. [PMID: 20204538]
28. U.S. Department of Health and Human Services Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents; 2009. Accessed at http://aidsinfo.nih. gov/contentfiles/AdultandAdolescentGL.pdf on 1 August 2010.
29. Centers for Disease Control and Prevention (CDC). CDC's HIV Prevention Progress in the United States; 2010. Accessed at www.cdc.gov/hiv/resources/ factsheets/PDF/cdcprev.pdf on 1 August 2010.
30. Centers for Disease Control and Prevention (CDC). Late HIV testing - 34 states, 1996-2005. MMWR Morb Mortal Wkly Rep. 2009;58:661-5. [PMID: 19553901]
31. Long EF, Brandeau ML, Owens DK. Potential population health outcomes and expenditures of HIV vaccination strategies in the United States. Vaccine. 2009;27:5402-10. [PMID: 19591796]
32. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford Univ Pr; 1996.
33. Bacon O, Lum P, Hahn J, Evans J, Davidson P, Moss A, et al. Commercial sex work and risk of HIV infection among young drug-injecting men who have sex with men in San Francisco. Sex Transm Dis. 2006;33:228-34. [PMID: 16565643]
34. Brisson M, Boily MC, Mâsse BR, Adrien A, Léaune V. Highlights of the sexual activity of the heterosexual population in the province of Quebec. Sex Transm Infect. 1999;75:296-9. [PMID: 10616351] (Pubitemid 29510704)
35. Fryar CD, Hirsch R, Porter KS, Kottiri B, Brody DJ, Louis T. Drug use and sexual behaviors reported by adults: United States, 1999-2002. Adv Data. 2007:1-14. [PMID: 17668724]
36. Johnson AM, Mercer CH, Erens B, Copas AJ, McManus S, Wellings K, et al. Sexual behaviour in Britain: partnerships, practices, and HIV risk behaviours. Lancet. 2001;358:1835-42. [PMID: 11741621] (Pubitemid 34008648)
37. Pathela P, Hajat A, Schillinger J, Blank S, Sell R, Mostashari F. Discordance between sexual behavior and self-reported sexual identity: a population-based survey of New York City men. Ann Intern Med. 2006;145:416-25. [PMID: 16983129] (Pubitemid 46768572)
38. Davis JO, Smith TW; National Opinion Research Center. General Social Surveys (GSS), 1972-2008.
39. Tyndall MW, Patrick D, Spittal P, Li K, O'Shaughnessy MV, Schechter MT. Risky sexual behaviours among injection drugs users with high HIV prevalence: implications for STD control. Sex Transm Infect. 2002;78 Suppl 1:i170-5. [PMID: 12083439]
40. Harawa NT, Greenland S, Bingham TA, Johnson DF, Cochran SD, Cunningham WE, et al. Associations of race/ethnicity with HIV prevalence and HIV-related behaviors among young men who have sex with men in 7 urban centers in the United States. J Acquir Immune Defic Syndr. 2004;35:526-36. [PMID: 15021318]
41. Kral AH, Lorvick J, Ciccarone D, Wenger L, Gee L, Martinez A, et al. HIV prevalence and risk behaviors among men who have sex with men and inject drugs in San Francisco. J Urban Health. 2005;82:i43-50. [PMID: 15738321] (Pubitemid 41442803)
42. MacKellar DA, Valleroy LA, Behel S, Secura GM, Bingham T, Celentano DD, et al. Unintentional HIV exposures from young men who have sex with men who disclose being HIV-negative. AIDS. 2006;20:1637-44. [PMID: 16868445]
43. Rietmeijer CA, Wolitski RJ, Fishbein M, Corby NH, Cohn DL. Sex hustling, injection drug use, and non-gay identification by men who have sex with men. Associations with high-risk sexual behaviors and condom use. Sex Transm Dis. 1998;25:353-60. [PMID: 9713915]
44. Spittal PM, Craib KJ, Wood E, Laliberté N, Li K, Tyndall MW, et al. Risk factors for elevated HIV incidence rates among female injection drug users in Vancouver. CMAJ. 2002;166:894-9. [PMID: 11949985]
45. Abbas UL, Anderson RM, Mellors JW. Potential impact of antiretroviral therapy on HIV-1 transmission and AIDS mortality in resource-limited settings. J Acquir Immune Defic Syndr. 2006;41:632-41. [PMID: 16652038]
46. Downs AM, De Vincenzi I. Probability of heterosexual transmission of HIV: relationship to the number of unprotected sexual contacts. European Study Group in Heterosexual Transmission of HIV. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;11:388-95. [PMID: 8601226]
47. Hollingsworth TD, Anderson RM, Fraser C. HIV-1 transmission, by stage of infection. J Infect Dis. 2008;198:687-93. [PMID: 18662132]
48. Kaplan EH. Modeling HIV infectivity: must sex acts be counted? J Acquir Immune Defic Syndr. 1990;3:55-61. [PMID: 2293643]
49. Mastro TD, de Vincenzi I. Probabilities of sexual HIV-1 transmission. AIDS. 1996;10 Suppl A:75-82.
50. Nicolosi A, Corrêa Leite ML, Musicco M, Arici C, Gavazzeni G, Lazzarin A. The efficiency of male-to-female and female-to-male sexual transmission of the human immunodeficiency virus: a study of 730 stable couples. Italian Study Group on HIV Heterosexual Transmission. Epidemiology. 1994;5:570-5. [PMID: 7841237]
51. Padian NS, Shiboski SC, Glass SO, Vittinghoff E. Heterosexual transmission of human immunodeficiency virus (HIV) in northern California: results from a ten-year study. Am J Epidemiol. 1997;146:350-7. [PMID: 9270414]
52. Wawer MJ, Gray RH, Sewankambo NK, Serwadda D, Li X, Laeyendecker O, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis. 2005;191:1403-9. [PMID: 15809897] (Pubitemid 40563350)
53. Caceres CF, van Griensven GJ. Male homosexual transmission of HIV-1. AIDS. 1994;8:1051-61. [PMID: 7986400]
54. Jacquez JA, Koopman JS, Simon CP, Longini IM Jr. Role of the primary infection in epidemics of HIV infection in gay cohorts. J Acquir Immune Defic Syndr. 1994;7:1169-84. [PMID: 7932084]
55. Vittinghoff E, Douglas J, Judson F, McKirnan D, MacQueen K, Buchbinder SP. Per-contact risk of human immunodeficiency virus transmission between male sexual partners. Am J Epidemiol. 1999;150:306-11. [PMID: 10430236] (Pubitemid 29344958)
56. Long EF, Brandeau ML, Galvin CM, Vinichenko T, Tole SP, Schwartz A, et al. Effectiveness and cost-effectiveness of strategies to expand antiretroviral therapy in St. Petersburg, Russia. AIDS. 2006;20:2207-15. [PMID: 17086061] (Pubitemid 44684712)
57. Zaric GS, Barnett PG, Brandeau ML. HIV transmission and the cost-effectiveness of methadone maintenance. Am J Public Health. 2000;90:1100-11. [PMID: 10897189]
58. Taylor A, Hutchinson S, Lingappa J, Wadd S, Ahmed S, Gruer L, et al. Severe illness and death among injecting drug users in Scotland: a case-control study. Epidemiol Infect. 2005;133:193-204. [PMID: 15816144] (Pubitemid 40439299)
59. Harris ZK. Efficient allocation of resources to prevent HIV infection among injection drug users: the Prevention Point Philadelphia (PPP) needle exchange program. Health Econ. 2006;15:147-58. [PMID: 16145716]
60. Wall SD, Olcott EW, Gerberding JL. AIDS risk and risk reduction in the radiology department. AJR Am J Roentgenol. 1991;157:911-7. [PMID: 1927808]
61. Kaplan EH, Heimer R. A model-based estimate of HIV infectivity via needle sharing. J Acquir Immune Defic Syndr. 1992;5:1116-8. [PMID: 1403641]
62. Cleary PD, Van Devanter N, Rogers TF, Singer E, Shipton-Levy R, Steilen M, et al. Behavior changes after notification of HIV infection. Am J Public Health. 1991;81:1586-90. [PMID: 1746654]
63. Higgins DL, Galavotti C, O'Reilly KR, Schnell DJ, Moore M, Rugg DL, et al. Evidence for the effects of HIV antibody counseling and testing on risk behaviors. JAMA. 1991;266:2419-29. [PMID: 1920748]
64. Honiden S, Sundaram V, Nease RF, Holodniy M, Lazzeroni LC, Zolopa A, et al. The effect of diagnosis with HIV infection on health-related quality of Life. Qual Life Res. 2006;15:69-82. [PMID: 16411032] (Pubitemid 43102473)
65. Tengs TO, Lin TH. A meta-analysis of utility estimates for HIV/AIDS. Med Decis Making. 2002;22:475-81. [PMID: 12458977]
66. Joyce VR, Barnett PG, Bayoumi AM, Griffin SC, Kyriakides TC, Yu W, et al. Health-related quality of life in a randomized trial of antiretroviral therapy for advanced HIV disease. J Acquir Immune Defic Syndr. 2009;50:27-36. [PMID: 19295332]
67. Schackman BR, Goldie SJ, Freedberg KA, Losina E, Brazier J, Weinstein MC. Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS. Med Decis Making. 2002;22:27-38. [PMID: 11833663] (Pubitemid 34087688)
68. Vernazza P, Hirschel B, Bernasconi E, Flepp M. HIV transmission under highly active antiretroviral therapy [Letter]. Lancet. 2008;372:1806-7. [PMID: 19027479]
69. Wilson DP, Law MG, Grulich AE, Cooper DA, Kaldor JM. Relation between HIV viral load and infectiousness: a model-based analysis. Lancet. 2008; 372:314-20. [PMID: 18657710]
70. McCormick AW, Walensky RP, Lipsitch M, Losina E, Hsu H, Weinstein MC, et al. The effect of antiretroviral therapy on secondary transmission of HIV among men who have sex with men. Clin Infect Dis. 2007;44:1115-22. [PMID: 17366461] (Pubitemid 46580284)
71. Cohen MS, Gay C, Kashuba AD, Blower S, Paxton L. Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med. 2007;146:591-601. [PMID: 17438318] (Pubitemid 351650540)
72. Joint United Nations Programme on HIV/AIDS (UNAIDS). 2008 Report on the Global AIDS Epidemic. Accessed at www.unaids.org/en/KnowledgeCentre/HIVData/ GlobalReport/2008/2008-Global-report.asp on 1 August 2010.
73. CensusScope. United States Age Distribution. 2000. Accessed at www .censusscope.org/us/chart-age.html on 1 August 2010.
74. Evans JL, Hahn JA, Page-Shafer K, Lum PJ, Stein ES, Davidson PJ, et al. Gender differences in sexual and injection risk behavior among active young injection drug users in San Francisco (the UFO Study). J Urban Health. 2003;80:137-46. [PMID: 12612103] (Pubitemid 37486160)
75. Friedman SR, Tempalski B, Cooper H, Perlis T, Keem M, Friedman R, et al. Estimating numbers of injecting drug users in metropolitan areas for structural analyses of community vulnerability and for assessing relative degrees of service provision for injecting drug users. J Urban Health. 2004;81:377-400. [PMID: 15273263]
76. Centers for Disease Control and Prevention (CDC). HIV and AIDS among Gay and Bisexual Men. Accessed at www.cdc.gov/nchhstp/newsroom/docs/FastFacts-MSM- FINAL508COMP.pdf on 1 August 2010.
77. Centers for Disease Control and Prevention (CDC). Cases of HIV Infection and AIDS in the United States and Dependent Areas, 2006. HIV/AIDS Surveillance Report, Volume 18. Accessed at www.cdc.gov/hiv/topics/surveillance/resources/ reports/2006report/default.htm on 1 August 2010.
78. Arias E, Rostron BL, Tejada-Vera B. United States life tables, 2005. Natl Vital Stat Rep. 2010;58:1-132. [PMID: 20578408]
79. Siegfried N, Muller M, Deeks JJ, Volmink J. Male circumcision for prevention of heterosexual acquisition of HIV in men. Cochrane Database Syst Rev. 2009:CD003362. [PMID: 19370585]
80. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med. 2005;2:e298. [PMID: 16231970]
81. Desai K, Boily MC, Garnett GP, Mâsse BR, Moses S, Bailey RC. The role of sexually transmitted infections in male circumcision effectiveness against HIV-insights from clinical trial simulation. Emerg Themes Epidemiol. 2006;3:19. [PMID: 17187662] (Pubitemid 46127300)
82. Centers for Disease Control and Prevention (CDC). Persons tested for HIV - United States, 2006. MMWR Morb Mortal Wkly Rep. 2008;57:845-9. [PMID: 18685551]
83. Teshale EH, Kamimoto L, Harris N, Li J, Wang H, McKenna MT. Estimated Number of HIV-infected Persons Eligible for and Receiving HIV Antiretroviral Therapy, 2003-United States [Abstract]. Proceedings of the 12th Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts, 22-25 February 2005.
84. Fryback DG, Dasbach EJ, Klein R, Klein BE, Dorn N, Peterson K, et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making. 1993;13:89-102. [PMID: 8483408] (Pubitemid 23113445)
85. Holtgrave DR, Pinkerton SD. Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16:54-62. [PMID: 9377126]
86. Bozzette SA, Joyce G, McCaffrey DF, Leibowitz AA, Morton SC, Berry SH, et al; HIV Cost and Services Utilization Study Consortium. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N Engl J Med. 2001;344:817-23. [PMID: 11248159]
87. Schackman BR, Gebo KA, Walensky RP, Losina E, Muccio T, Sax PE, et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care. 2006;44:990-7. [PMID: 17063130] (Pubitemid 44674030)
88. Hutchinson AB, Farnham PG, Dean HD, Ekwueme DU, del Rio C, Kamimoto L, et al. The economic burden of HIV in the United States in the era of highly active antiretroviral therapy: evidence of continuing racial and ethnic differences. J Acquir Immune Defic Syndr. 2006;43:451-7. [PMID: 16980906]
89. World Health Organization (WHO). Global Health Observatory. Accessed at www.who.int/gho/en/ on 1 August 2010.
90. Centers for Medicaid and Medicare Services. Medicaid Fee Schedule. Accessed at www.med-quest.us/PDFs/Provider%20Memos/Medicaid%20Fee%20Schedule.pdf on 1 August 2010.
91. Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, et al; NA-ACCORD Investigators. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009;360:1815-26. [PMID: 19339714]
92. Freedberg KA, Losina E, Weinstein MC, Paltiel AD, Cohen CJ, Seage GR, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med. 2001;344:824-31. [PMID: 11248160]
93. Bendavid E, Wood R, Katzenstein DA, Bayoumi AM, Owens DK. Expanding antiretroviral options in resource-limited settings - a cost-effectiveness analysis. J Acquir Immune Defic Syndr. 2009;52:106-13. [PMID: 19448557]
94. Goldie SJ, Yazdanpanah Y, Losina E, Weinstein MC, Anglaret X, Walensky RP, et al. Cost-effectiveness of HIV treatment in resource-poor settings - the case of Côte d'Ivoire. N Engl J Med. 2006;355:1141-53. [PMID: 16971720] (Pubitemid 44394920)
95. Anaya HD, Hoang T, Golden JF, Goetz MB, Gifford A, Bowman C, et al. Improving HIV screening and receipt of results by nurse-initiated streamlined counseling and rapid testing. J Gen Intern Med. 2008;23:800-7. [PMID: 18421508]
96. Zetola NM, Bernstein K, Ahrens K, Marcus JL, Philip S, Nieri G, et al. Using surveillance data to monitor entry into care of newly diagnosed HIV-infected persons: San Francisco, 2006-2007. BMC Public Health. 2009;9:17. [PMID: 19144168]
97. Hoerger TJ, Harris R, Hicks KA, Donahue K, Sorensen S, Engelgau M. Screening for type 2 diabetes mellitus: a cost-effectiveness analysis. Ann Intern Med. 2004;140:689-99. [PMID: 15126252]
98. Plevritis SK, Kurian AW, Sigal BM, Daniel BL, Ikeda DM, Stockdale FE, et al. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. JAMA. 2006;295:2374-84. [PMID: 16720823]
99. Hollingsworth TD, Anderson RM, Fraser C. Has the role of primary HIV been overstated? [Abstract]. Proceedings from the 13th Conference on Retroviruses and Opportunistic Infections, Denver, Colorado, 5-8 February 2006.
100. Kelly JA, Morin SF, Remien RH, Steward WT, Higgins JA, Seal DW, et al. Lessons learned about behavioral science and acute/early HIV infection. The NIMH Multisite Acute HIV Infection Study: V. AIDS Behav. 2009;13:1068-74. [PMID: 19504179]
101. Kerndt PR, Dubrow R, Aynalem G, Mayer KH, Beckwith C, Remien RH, et al. Strategies used in the detection of acute/early HIV infections. The NIMH Multisite Acute HIV Infection Study: I. AIDS Behav. 2009;13:1037-45. [PMID: 19495954]
102. Pinkerton SD. How many sexually-acquired HIV infections in the USA are due to acute-phase HIV transmission? AIDS. 2007;21:1625-9. [PMID: 17630558]
103. Prabhu VS, Hutchinson AB, Farnham PG, Sansom SL. Sexually acquired HIV infections in the United States due to acute-phase HIV transmission: an update [Letter]. AIDS. 2009;23:1792-4. [PMID: 19684485]
104. Walensky RP, Weinstein MC, Kimmel AD, Seage GR 3rd, Losina E, Sax PE, et al. Routine human immunodeficiency virus testing: an economic evaluation of current guidelines. Am J Med. 2005;118:292-300. [PMID: 15745728] (Pubitemid 40312641)